P/B
1,7
Elanco Animal Health
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
$11.5B
Market Cap • 9/22/2026
2018
(8 years)
Founded
2018
(8 years ago)
IPO
NYSE
Listing Exchange
United States
Country
Valuation
P/S
2,3
P/EBITDA
14,8
P/OCF
18,6
P/FCF
30,2
P/E
—
BVPS
13,1
EPS
—
Market Cap
Market Cap
11,5B
EV
14,8B
EV/Revenue
3
EV/EBITDA
19,2
EV/EBIT
181
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-2,1B
Profitability
Gross Margin
55,4%
EBITDA Margin
15,4%
EBIT Margin
1,6%
Net Margin
—
D&A/EBITDA
71,7%
R&D/Revenue
7,4%
Capex/Revenue
4,7%
Capex/D&A
34,3%
Capex/OCF
38,6%
SBC/OCF
12%
% PPE
10,4%
% Goodwill
35,7%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
2%
CAGR Net Income 5Y
-23,2%
CAGR EPS 5Y
-22,8%
Leverage
N.D./EBITDA
4,4
Debt/Equity
0%
Current Ratio
2,1
Quick Ratio
0,9
Interest Coverage
33,1%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!